Policy & Advocacy

Learn How ASGCT Impacted FDA Guidance for CGT

Chiagbanwe (ChiChi) Enwere, MPH | March 14, 2023

FDA acknowledged Society comments in recent guidance documents.

Policy & Advocacy

Read Full Story

ASGCT Members Share Science Behind Immunotherapies with Federal Policymakers

Margarita Valdez Martínez | February 23, 2023

Last month, ASGCT members collaborated with the House Cancer Caucus on a briefing on innovative immunotherapies for cancer treatment to improve patient access. The Society is grateful for the opportunity to better inform regulatory and legislative policymakers about gene and cell therapies. 

Policy & Advocacy

Read Full Story

HHS Secretary Announces CGT Access Model

Margarita Valdez Martínez | February 15, 2023

CMS announces three new payment models for testing by the Center for Medicare and Medicaid Innovation. A proposed Cell and Gene Therapy Access Model has the potential for a far-reaching impact on the CGT field.

Policy & Advocacy

Read Full Story

Looking Back at a Year of Advocacy Progress

Caitlin McCombs, MBA | February 03, 2023

Learn what ASGCT's Policy & Advocacy team accomplished in 2022 and what they're excited about in 2023.

Policy & Advocacy

Read Full Story

FDA Approves First CAR T-Cell Therapy for ALL

ASGCT Staff | October 14, 2021

This marks approval of a second disease indication for Tecartus, which received accelerated approval for the treatment of adults with r/r mantle cell lymphoma in July 2020.

Policy & Advocacy

Read Full Story

ASGCT Gears Up for 2021 Policy Progress

Francesca Cook, MPH | January 12, 2021

Read about the Society's policy and advocacy successes of 2020 and our goals for 2021.

Policy & Advocacy

Read Full Story

ASGCT Holds First Joint Meeting With Brazilian Association

ASGCT Staff | December 03, 2020

Speakers addressed the scientific and infrastructural requirements for successful translation into clinical research for oncology, hemophilia, and sickle cell disease.

Policy & Advocacy

Read Full Story

Policy Summit’s Sickle Cell Disease Session Emphasizes Patient Access

Emily Nettesheim | October 05, 2020

The Policy Summit session on sickle cell disease focused on patient education and the policy reforms necessary to bring curative gene therapy treatments to the millions of patients suffering from SCD around the world.

Policy & Advocacy   |   Policy Summit

Read Full Story